Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

BIOA

BioAge Labs Inc

Last Close
5.55
Nov 13 • 3:59 PM ET Dollar change-0.10 Percentage change(-1.77%)
Aftermarket Close
5.37
Aftermarket • 7:53 PM ET Dollar change-0.18 Percentage change(-3.32%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Drug Manufacturers - Specialty & Generic USA Micro NASD
Peers: ALT GPCR EYPT KOD NAMS MLYS OCUL CRBP VKTX NVO
 | Held by: VTI IWM VXF XPH IWN IBB DFAS VTWO FESM SCHA
Scroll to Statements
Index
RUT
Market Cap
255.07M
Enterprise Value
-25.84M
Income
-107.80M
Sales
8.60M
Book/sh
7.54
Cash/sh
6.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
62
IPO
Sep 26, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
29.66
P/B
0.74
P/C
0.90
P/FCF
-
EV/EBITDA
-
EV/Sales
-3.00
Quick Ratio
15.51
Current Ratio
15.51
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-2.55
EPS next Y
-2.52
EPS next Q
-0.74
EPS this Y
-15.82%
EPS next Y
2.98%
EPS next 5Y
-3.84%
EPS past 3/5Y
-24.49% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-20.81%
Sales Y/Y TTM
45.33%
EPS Q/Q
-29.72%
Sales Q/Q
-85.49%
Earnings
Nov 05 AMC
EPS/Sales Surpr.
-15.01% -79.83%
Insider Own
31.58%
Insider Trans
-0.43%
Inst Own
65.05%
Inst Trans
10.27%
ROA
-32.05%
ROE
-34.56%
ROIC
-30.94%
Gross Margin
96.72%
Oper. Margin
-1401.81%
Profit Margin
-1253.60%
SMA20
-0.92%
SMA50
-15.91%
SMA200
-63.28%
Trades
Shs Outstand
45.95M
Shs Float
31.44M
Short Float
11.85%
Short Ratio
5.10
Short Interest
3.73M
52W High
25.95 -78.62%
52W Low
4.81 15.38%
Volatility
7.92% 8.27%
ATR (14)
0.44
RSI (14)
41.92
Beta
1.20
Rel Volume
0.59
Avg Volume
730.76K
Volume
427,518
Perf Week
3.93%
Perf Month
3.74%
Perf Quarter
-46.63%
Perf Half Y
-68.57%
Perf YTD
-58.05%
Perf Year
-28.11%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
1.67
Target Price
29.50
Prev Close
5.65
Price
5.55
Change %
-1.77%
Consensus
Buy
Avg. Price Target
$29.50
Implied Upside
+431.5%
Analysts10incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 12, 2026Initiated
UBS logoUUBS
Neutral$8+44.1%
May 27, 2026Initiated
RRoth Capital
Buy$36+548.6%
May 13, 2026Initiated
BBTIG Research
Buy$40+620.7%
Mar 27, 2026Initiated
NNeedham
Buy$50+800.9%
Feb 25, 2026Initiated
OPY logoOOppenheimer
Outperform$60+981.1%
Feb 18, 2026Upgrade
JEF logoJJefferies
Hold → Buy$62+1,017.1%
Jan 27, 2026Initiated
PPiper Sandler
Overweight$73+1,215.3%
Dec 05, 2025Upgrade
MS logoMMorgan Stanley
Underweight → Equal-Weight$12+116.2%
Oct 22, 2025Upgrade
C logoCCitigroup
Neutral → Buy$10+80.2%
Feb 28, 2025Initiated
WWilliam Blair
Mkt Perform
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barton ShanePrincipal Accounting OfficerJun 29 '26Option Exercise6.6139,718262,54242,350Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Option Exercise6.5320,216132,01720,216Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 29 '26Sale25.2142,3501,067,5760Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Sale25.1920,216509,1760Jul 01 04:27 PM
Barton ShaneOfficerJun 30 '26Proposed Sale25.1920,216509,177Jun 30 04:21 PM
Barton ShaneOfficerJun 29 '26Proposed Sale25.2142,3501,067,578Jun 29 04:35 PM
GOLDSTEIN DOV A MDChief Financial OfficerApr 23 '26Option Exercise4.383,54215,51436,575Apr 24 04:19 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Option Exercise5.058,82044,5728,820Apr 03 04:07 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Sale17.818,820157,0840Apr 03 04:07 PM
RUBIN PAUL DOfficerApr 01 '26Proposed Sale17.818,820157,084Apr 01 10:53 AM
RUBIN PAUL DChief Medical OfficerMar 02 '26Option Exercise4.777,43335,4707,433Mar 03 04:46 PM
RUBIN PAUL DChief Medical OfficerMar 02 '26Sale20.307,433150,8900Mar 03 04:46 PM
GOLDSTEIN DOV A MDChief Financial OfficerMar 01 '26Option Exercise4.383,54215,51433,033Mar 03 04:44 PM
RUBIN PAUL DOfficerMar 02 '26Proposed Sale20.037,433148,883Mar 02 10:17 AM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Option Exercise4.777,43335,4707,433Feb 03 04:26 PM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Sale18.757,433139,3690Feb 03 04:26 PM
GOLDSTEIN DOV A MDChief Financial OfficerFeb 01 '26Option Exercise4.383,54115,51029,491Feb 03 04:23 PM
RUBIN PAUL DOfficerFeb 02 '26Proposed Sale18.757,433139,369Feb 02 09:43 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 16 '26Option Exercise4.383,54215,51425,950Jan 21 04:20 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Option Exercise8.3927,000226,53049,408Jan 15 04:22 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Sale19.7027,000531,82822,408Jan 15 04:22 PM
Fortney KristenChief Executive OfficerJan 13 '26Sale18.12233,1074,223,036976,949Jan 15 04:20 PM
Fortney Kristen10% OwnerJan 13 '26Proposed Sale18.00233,1074,195,926Jan 13 04:36 PM
GOLDSTEIN DOV A MDOfficerJan 13 '26Proposed Sale19.7027,000531,828Jan 13 04:16 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Option Exercise4.777,43335,4707,433Jan 06 04:24 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Sale12.857,43395,4900Jan 06 04:24 PM
RUBIN PAUL DOfficerJan 02 '26Proposed Sale13.417,43399,677Jan 02 12:56 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Option Exercise6.5718,000118,26018,000Dec 11 04:21 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Sale12.0018,000216,0000Dec 11 04:21 PM
RUBIN PAUL DOfficerDec 09 '25Proposed Sale12.0018,000216,000Dec 09 11:23 AM
RUBIN PAUL DChief Medical OfficerDec 04 '25Option Exercise4.1168,897283,16768,897Dec 05 06:20 PM
RUBIN PAUL DChief Medical OfficerDec 04 '25Sale10.1968,897701,9090Dec 05 06:20 PM
RUBIN PAUL DOfficerDec 04 '25Proposed Sale10.1968,897701,912Dec 04 04:30 PM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Co-FounderDr. Kristen Fortney Ph.D.
Co-FounderDr. Eric Morgen M.D.
Chief Medical Officer & Executive VP of ResearchDr. Paul D. Rubin M.D.
M.D.Dr. Dov A. Goldstein M.B.A.
Senior Vice President of Finance & AccountingMr. Shane Barton CPA
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)